Related Experiment Video
Updated: Jun 11, 2025
Targeted and Selective Treatment of Pluripotent Stem Cell-derived Teratomas Using External Beam Radiation in a Small-animal Model
Published on: February 17, 2019
Scutellarein treats neuroblastoma by regulating the expression of multiple targets
Chen-Yang Zhai1, Ji-Sheng Fan2, Rong-Ping Zhang3
1Institute of Neuroscience Kunming Medical University Kunming China.
Abstract:
The aim of this study is to investigate the effect of scutellarein on the proliferation of neuroblastoma cells and the underlying mechanism. Six cell lines were used with drug intervention. Cell Counting Kit-8 was used to select the best, namely, SH-SY5Y, and then its IC50 value was determined. To further investigate the mechanism of scutellarin affecting SH-SY5Y proliferation, quantitative real-time polymerase chain reaction (qRT-PCR) was used to detect the expression levels of 11 factors. Scutellarin administration with 300 μM significantly reduced the number of SH-SY5Y, especially on the 3rd day of exposure to scutellarin. The IC50 value of scutellarin in SH-SY5Y cells was determined to be 117.8 μM. But the practical results showed that 300 μM was the optimal concentration of scutellarin. qRT-PCR further detected upregulated maternally expressed gene 3 (MEG3), oncogene c-Fos (c-FOS), and c-jun and downregulated M2 isoform of pyruvate kinase (PKM2), non-SMC Condensin I Complex Subunit H (NCAPH), epidermal growth factor receptor (EGFR), transforming growth factor (TGF)-β1, and TGF-α, suggesting that scutellarin with 300 μM volume inhibited the survival of SH-SY5Y by regulating the expression of these 8 factors. Scutellarin could be a novel drug for the treatment of neuroblastoma, and its underlying mechanism may be related to the upregulated levels of MEG3, c-FOS, and c-jun and downregulated the expression of PKM2, NCAPH, EGFR, TGF-β1, and TGF-α.
Insights
Scutellarin effectively inhibits neuroblastoma cell growth by altering key gene expressions. This natural compound shows potential as a novel therapeutic agent for neuroblastoma treatment.
Area of Science:
- Pharmacology and Molecular Biology
- Cancer Research
- Neuro-oncology
Background:
- Neuroblastoma is a pediatric cancer with limited treatment options.
- Natural compounds are being explored for their therapeutic potential against cancer.
- Scutellarin, a flavonoid, has shown various biological activities.
Purpose of the Study:
- To investigate the anti-proliferative effects of scutellarin on neuroblastoma cells.
- To elucidate the underlying molecular mechanisms of scutellarin's action.
- To evaluate scutellarin as a potential novel drug for neuroblastoma treatment.
Main Methods:
- Screening of six neuroblastoma cell lines to identify the most responsive, SH-SY5Y.
- Determination of the half-maximal inhibitory concentration (IC50) of scutellarin.
- Quantitative real-time polymerase chain reaction (qRT-PCR) to analyze gene expression changes.
Main Results:
- Scutellarin (300 μM) significantly inhibited SH-SY5Y cell proliferation, particularly by day 3.
- The determined IC50 value for scutellarin in SH-SY5Y cells was 117.8 μM.
- Gene expression analysis revealed upregulation of MEG3, c-FOS, and c-jun, and downregulation of PKM2, NCAPH, EGFR, TGF-β1, and TGF-α.
Conclusions:
- Scutellarin demonstrates significant anti-proliferative activity against SH-SY5Y neuroblastoma cells.
- The mechanism involves the modulation of specific genes, including MEG3, c-FOS, c-jun, PKM2, NCAPH, EGFR, TGF-β1, and TGF-α.
- Scutellarin holds promise as a potential novel therapeutic agent for neuroblastoma.
